AbbVie raises long-term outlook for Skyrizi and Rinvoq revenues

AbbVie is reaffirming its expectations for a high single-digit compound annual revenue growth rate through 2029. This guidance assumes 2024 as the base year in the compound annual growth rate calculation. AbbVie is raising its long-term outlook for Skyrizi and Rinvoq revenues. The company now expects combined Skyrizi and Rinvoq 2027 revenues of more than $27B, an increase of approximately $6B compared to previous guidance for combined revenues of more than $21B in 2027. AbbVie is also raising its long-term outlook for Ubrelvy and Qulipta revenues. The company now expects peak combined Ubrelvy and Qulipta revenues of more than $3B, an increase of approximately $1B compared to previous guidance for peak revenues of more than $1B for each asset.